Thimerosal and autism? A plausible hypothesis that should not be dismissed

Medical Hypotheses

Volumn 62, Issue 5, 2004, Pages 788-794

  Blaxill, Mark F ^a,b   Redwood, Lyn ^a   Bernard, Sallie ^a  

^a Safe Minds ^*  (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCURY; RHESUS D ANTIBODY; THIOMERSAL; VACCINE;

AUTISM; EVIDENCE BASED MEDICINE; EXPERIMENT; HUMAN; HYPOTHESIS; MEDICAL RESEARCH; MERCURIALISM; NEUROPATHOLOGY; NONHUMAN; OBSERVER VARIATION; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 1942500225     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.033     Document Type: Article

References (52)

1. CDC. Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR 1999;49(26):563-65.
2. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses 2001;56:462-71.
3. Bernard S, Enayati A, Roger H, Binstock T, Redwood L. The role of mercury in the pathogenesis of autism. Mol Psychiatr 2002;7:S42-3.
4. Institute of Medicine. Stratton K, Gable A, McCormick M, editors. Immunization safety review: thimerosal containing vaccines and neurodevelopmental disorders. Washington, DC: National Academy Press; 2001.
5. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002;360(9347):1737-41.
6. Makani S, Gollapudi S, Yel L, Chiplunkar S, Gupta S. Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway. Genes Immun 2002;3(5):270-8.
7. Baskin DS, Ngo H, Didenko W. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol Sci 2003;74(2):361-8, Epub 2003 May 28.
8. Westphal GA, Asgari S, Schulz TG, Bunger J, Muller M, Hallier E. Thimerosal induces micronuclei in the cytochalasin B block micronucleus test with human lymphocytes. Arch Toxicol 2003;77(1):50-5, Epub 2002 Nov 06.
9. Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med 2003;228(6):660-4.
10. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxic 2003;22(4):277-85.
11. Nelson KB, Bauman ML. Thimerosal and autism? Pediatrics 2003;111(3):674-9.
12. Goyer RA, Clarkson TW. Toxic effects of metals. In: Klaassen C, editor. Casarett & Doull's toxicology: the basic science of poisons. 6th ed. New York: McGraw-Hill Medical Publishing Division; 2001.
13. Kondo K. Congenital Minamata disease: warnings from Japan's experience. J Child Neurol 2000;15(7):458-64.
14. Creek DB. Pink disease (infantile acrodynia). J Pediatr 1953;42(2):239-60.
15. Warkany J, Hubbard DM. Acrodynia and mercury. J Pediatr 1953;42:365-86.
16. Igata A. Epidemiological and clinical features of Minamata disease. Environ Res 1993;63(1):157-69.
17. Rocaz Ch. L'Acrodynie infantile. Paris: G. Doin & Cie; 1930.
18. Cinca I, Dumitrescu I, Onaca P, Serbanescu A, Nestorescu B. Accidental ethyl mercury poisoning with nervous system, skeletal muscle, and myocardium injury. J Neurol Neurosurg Psychiatr 1980;43(2):143-9.
19. Nierenberg DW, Nordgren RE, Chang MB, Siegler RW, Blayney MB, Hochberg F, et al. Delayed cerebellar disease and death after accidental exposure to dimethylmercury. N Engl J Med 1998;338(23):1672-6.
20. Choi BH, Lapham LW, Amin-Zaki L, Saleem T. Abnormal neuronal migration, deranged cerebral cortical organization, and diffuse white matter astrocytosis of human fetal brain: a major effect of methylmercury poisoning in utero. J Neuropathol Exp Neurol 1978;37(6):719-33.
21. Magos L, Brown AW, Sparrow S, Bailey E, Snowden RT, Skipp WR. The comparative toxicology of ethyl- and methylmercury. Arch Toxicol 1985;57(4):260-7.
22. Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J Appl Toxicol 2001;21(1):1-5.
23. Magos L. Answers to questions on the toxicity of ethylmercury: prepared for the Institute of Medicine Immunization Safety Review Committee. July 2, 2001 b. Available from http://www.iom.edu/iom/iomhome.nsf/wfiles/ethg/$file/ ethg.pdf.
24. Kerper LE, Ballatori N, Clarkson TW. Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol 1992;262(5 Pt 2):R761-5.
25. Smith QR, Stoll J. Blood-brain barrier amino acid transport. In: Pardridge WM, editor. Introduction to the blood--brain barrier. Cambridge: Cambridge University Press; 1998. p. 188-97.
26. Sorensen FW, Larsen JO, Eide R, Schionning JD. Neuron loss in cerebellar cortex of rats exposed to mercury vapor: a stereological study. Acta Neuropathol 2000;100(1):95-100.
27. Sakamoto M, Kakita A, Wakabayashi K, Takahashi H, Nakano A, Akagi H. Evaluation of changes in methylmercury accumulation in the developing rat brain and its effects: a study with consecutive and moderate dose exposure throughout gestation and lactation periods. Brain Res 2002;949(1-2):51-9.
28. Chuu JJ, Young YH, Liu SH, Lin-Shiau SY. Neurotoxicity of mercury sulfide in the vestibular ocular reflex system of guinea pigs. N-S Arch Pharmacol 2001;364(3):249-58.
29. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism. In: Bauman ML, Kemper TL, editors. The neurobiology of autism. Baltimore: Johns Hopkins University Press; 1994.
30. Counter SA. Neurophysiological anomalies in brainstem responses of mercury-exposed children of Andean gold miners. J Occup Environ Med 2003;45(1):87-9.
31. Murata K, Weihe P, Araki S, Budtz-Jorgensen E, Grandjean P. Evoked potentials in Faroese children prenatally exposed to methylmercury. Neurotoxicol Teratol 1999;21(4):471-2.
32. Verstraeten T, Davis R, DeStefano F. Thimerosal VSD study phase 1 (2/29/00). Obtained via Freedom of Information Act request.
33. Juul-Dam N, Townsend J, Courchesne E. Prenatal, perinatal, and neonatal factors in autism, pervasive developmental disorder-not otherwise specified, and the general population. Pediatrics 2001;107(4):E63.
34. Schober SE, Sinks TH, Jones RL, Bolger PM, McDowell M, Osterloh J, et al. Blood mercury levels in US children and women of childbearing age, 1999-2000. JAMA 2002;289:1667-74.
35. Bradstreet J, Geier DA, Kartzinel JJ, Adams JB, Geier MR. A case-control study of mercury burden in children with autistic spectrum disorders. J Am Phys Surg 2003;8:76-9.
36. Hoshino Y, Kumashiro H, Tashima Y, Tachibana R, Watanage M. The epidemiological study of autism in Fukushimaken. Folia Psychiatr Neurol Jpn 1982;36:115-24.
37. Marsh DO, Clarkson TW, Meters GJ, Davidson PW, Cox C, Cernichiari E, et al. The Seychelles study of fetal methyl-mercury exposure and childhood development: introduction. Neurotoxicology 1995;16(4):583-96.
38. Grandjean P, Weihe P, White RF, Debes F, Araki S, Yokoyama K, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotox Teratol 1997;19(6):417-28.
39. Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord 2002;32:207-15.
40. Fombonne E. The epidemiology of autism: a review. Psychol Med 1999;29(4):769-86.
41. Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? Ment Retard Dev Disabil Res Rev 2002;8:151-61.
42. Blaxill MF, Baskin DS, Spitzer WO. On Croen et al. (2002), The changing prevalence of autism in California. J Aut Devel Disord. 2003;33(2):223-26.
43. Blaxill MF. Any changes in prevalence of autism must be determined. BMJ 2002;324:296.
44. Byrd RS et al. Report to the legislature on the principal findings from the epidemiology of autism in California. The MIND Institute; October 17, 2002.
45. Croen LA, Grether JK. A response to Blaxill, Baskin and Spitzer on Croen et al., The changing prevalence of autism in California. J Aut Devel Disord 2003;33(2):227-29.
46. Burd L, Kerbeshian J, Klug MG, McCulloch K. A prevalence methodology for mental illness and developmental disorders in rural and frontier settings. Int J Circumpolar Health 2000;59(1):74-86.
47. Nylander L, Gillberg C. Screening for autism spectrum disorders in adult psychiatric out-patients: a preliminary report. Acta Psychiatr Scand 2001;103(6):428-34.
48. Treffert DA. Epidemiology of infantile autism. Arch Gen Psychiatr 1970;22(5):431-8.
49. Ritvo ER, Freeman BJ, Pingree C, Mason-Brothers A, Jorde L, Jenson WR, et al. The UCLA-University of Utah epidemiologic survey of autism: prevalence. Am J Psychiatr 1989;146(2):194-9.
50. Burd L, Fisher W, Kerbeshian J. A prevalence study of pervasive developmental disorders in North Dakota. J Am Acad Child Adolesc Psychiatr 1987;26(5):700-3.
51. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: The Brick Township, New Jersey, Investigation. Pediatrics 2001;108(5):1155-61.
52. Yeargin-Allsopp M, Rice C, Karapurkan T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA 2003;289:49-55.